Sign In
Buy XBI
$129.83
+2.07 (+1.62%)
At Close: Jun 03, 2026
3 Thematic Growth ETFs to Load Up on Right Now
10:30am, Saturday, 30'th Dec 2023
Thematic exchange-traded funds have become extremely popular investing vehicles. These three growth-oriented thematic ETFs stand out as superb buys right now.
3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
02:12pm, Friday, 29'th Dec 2023
The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a
These ETF strategies were big winners in 2023. Here's where one CFRA analyst sees them going next year.
06:40pm, Thursday, 28'th Dec 2023
Hello! This is MarketWatch reporter Isabel Wang bringing you this week's ETF Wrap. In this week's edition, we look at ETF strategies that have exploded in popularity in 2023, and whether they will con
Dr. Scott Gottlieb talks Big Pharma's buying spree
04:26pm, Wednesday, 27'th Dec 2023
Dr. Scott Gottlieb, joins 'Closing Bell' to discuss the government's regulation on the pharmaceutical industry.
Wedbush's Laura Chico talks biotech investing in 2024
05:21pm, Tuesday, 26'th Dec 2023
Laura Chico, Wedbush Biotech Analyst, joins 'Closing Bell Overtime' to talk investing in biotech.
Buy or bail on biotech: Here's what you need to know
01:40pm, Tuesday, 26'th Dec 2023
Biotech is up double digits this month. Piper Sandler says that the sector is breaking out.
3 Charts For Investors to Watch Tuesday: Bitcoin, Oil, XBI ETF
08:20am, Tuesday, 26'th Dec 2023
Here's our daily look at three charts linked to recent news-driven price moves, with key technical levels to monitor.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
07:31am, Monday, 18'th Dec 2023
Launched on 01/31/2006, the SPDR S&P Biotech ETF (XBI) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.
Biopharmaceutical Stocks: The Rally Has Just Begun
12:25pm, Thursday, 14'th Dec 2023
Biopharmaceutical sector valuations have become more attractive after a significant decline in 2021. Larger drug companies are making acquisitions and partnerships with small-cap stocks at generous pr
White House vs. Big Pharma: The battle to lower prices
04:30pm, Thursday, 07'th Dec 2023
Mizuho's Jared Holz and BMO Capital's Evan Seigerman join 'Power Lunch' to discuss the drug pricing battle between the Biden Administration and big pharma.
Top trades for 2024 encircle Big Tech, but their bonds are a better bet, Bank of America says
08:38am, Saturday, 02'nd Dec 2023
Top trades headed into the new year are encircling the Big Tech names, but not in the way many might think.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
07:31am, Monday, 20'th Nov 2023
Launched on 01/31/2006, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
It doesn't seem like there's too much momentum for healthcare stocks, says Mizuho's Jared Holz
12:07pm, Monday, 23'rd Oct 2023
Jared Holz, Mizuho healthcare sector specialist, joins 'Squawk on the Street' to discuss how Holz broadly sees the biotechnology sector, what distills the winners from losers in the healthcare space,
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
07:31am, Tuesday, 17'th Oct 2023
The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
4 Closed-End Fund Buys In The Month Of September 2023
10:06pm, Sunday, 15'th Oct 2023
September was the worst month for equities in 2023, but that's simply creating buying opportunities for the long-term investor. I added to four different positions in my CEF portfolio this month, thou
